TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
PYC Therapeutics Limited has announced the appointment of Peter Coleman as the new Independent Non-Executive Chair, effective after the 2025 Annual General Meeting. This leadership change is part of a broader board renewal process, with current Chair Alan Tribe stepping down. Coleman, with a background in corporate governance and mergers, is expected to guide PYC through its next growth phase, potentially opening new commercial avenues. The company is also undergoing changes in its executive team, with Andrew Taylor resigning as co-Company Secretary and CFO, while Kevin Hart will continue as the sole Company Secretary. These strategic shifts aim to align with long-term shareholder value creation and strengthen PYC’s position in the RNA therapy market.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing precision RNA therapies for genetic diseases with no available treatment options. The company leverages a proprietary drug delivery platform to enhance the efficacy of precision medicines in the RNA therapeutic class, targeting monogenic diseases for higher clinical success rates.
Average Trading Volume: 704,069
Technical Sentiment Signal: Hold
Current Market Cap: A$691.2M
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.